Related Experiment Video
Updated: Sep 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Therapeutic Strategies for Resectable Stage-IIIA N2 Non-Small Cell Lung Cancer Patients: A Network Meta-Analysis
Ziyang Shen1, Ya Lu1, Ying Sui1
1Department of Malignant Lung Tumor Targeting Therapy Research Center, Jiangsu Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China.
Background:
The National Comprehensive Cancer Network (NCCN) guidelines did not give an explicit comparison of the efficacy between surgery and radiotherapy in treating Stage-III N2 non-small cell lung cancer (NSCLC) patients, leaving a paucity for clinical reference. Through this study, we try to locate the optimum treatment strategy including surgical type for these patients.
Methods:
A systematic literature search was performed from PubMed, Cochrane Library, Embase, and Google Scholars. The endpoints were overall survival (OS), mean OS, and progression-free survival (PFS). The treatments comprised radiotherapy, lobectomy, and pneumonectomy. Network meta-analysis was carried out for calculating the odds ratio (OR) for binary variants. All the analyses implemented Stata 17.0 MP.
Results:
Eight clinical trials reporting 1756 patients met the inclusion criteria. Radiotherapy and surgery were equivalent in improving patients' OS (OR = 0.842, 95% confidence interval [CI]: [0.645, 1.099]). The mean OS of patients were similar in terms of radiotherapy, lobectomy, and pneumonectomy. Besides, radiotherapy and surgery had equivalent effects in improving PFS (OR = 0.896, 95% CI: [0.718, 1.117]).
Conclusions:
Since lobectomy and pneumonectomy following neoadjuvant treatments had equivalent efficacy in prolonging OS for patients with stage-IIIA N2 NSCLC compared with definitive radiotherapy, young patients with favorable performance status (0) should try surgery to pursue better prognosis while elderly patients with unfavorable PS or radiosensitive pathology types should accept definitive radiotherapy. More high-quality clinical trials are needed to support our findings.
Insights
For Stage-III N2 non-small cell lung cancer (NSCLC), surgery and radiotherapy show similar efficacy for overall survival (OS) and progression-free survival (PFS). Treatment choice may depend on patient factors like age and performance status.
Area of Science:
- Oncology
- Thoracic Surgery
- Radiation Oncology
Background:
- National Comprehensive Cancer Network (NCCN) guidelines lack explicit comparisons between surgery and radiotherapy for Stage-III N2 non-small cell lung cancer (NSCLC).
- This gap creates a need for clinical guidance on optimal treatment strategies, including surgical approaches.
Purpose of the Study:
- To compare the efficacy of surgery versus radiotherapy in treating Stage-III N2 NSCLC.
- To identify the optimal treatment strategy, considering different surgical options.
Main Methods:
- Systematic literature search across PubMed, Cochrane Library, Embase, and Google Scholars.
- Network meta-analysis of eight clinical trials involving 1756 patients.
- Endpoints included overall survival (OS) and progression-free survival (PFS).
Main Results:
- Radiotherapy and surgery demonstrated equivalent efficacy in improving patients' OS (OR=0.842, 95% CI: [0.645, 1.099]).
- Mean OS was similar across radiotherapy, lobectomy, and pneumonectomy.
- Equivalent effects were observed for improving PFS (OR=0.896, 95% CI: [0.718, 1.117]).
Conclusions:
- Lobectomy and pneumonectomy following neoadjuvant treatments show equivalent efficacy to definitive radiotherapy for Stage-IIIA N2 NSCLC in prolonging OS.
- Younger patients with good performance status may benefit from surgery.
- Elderly patients or those with radiosensitive types may be better suited for definitive radiotherapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...